The Experts below are selected from a list of 1449 Experts worldwide ranked by ideXlab platform

Niels Zorger - One of the best experts on this subject based on the ideXlab platform.

  • Treatment of Acute Hemoptysis by Bronchial Artery Embolization with the Liquid Embolic Agent Ethylene Vinyl Alcohol Copolymer
    Journal of vascular and interventional radiology : JVIR, 2017
    Co-Authors: Isabelle Ayx, René Müller-wille, Christian Stroszczynski, Walter A. Wohlgemuth, Michael Pfeifer, Marc Lepiorz, Heinrich Hubauer, Holger Goessmann, Niels Zorger
    Abstract:

    Abstract Purpose To determine the technical and clinical success of bronchial artery embolization (BAE) with the Liquid Embolic Agent ethylene vinyl alcohol (EVOH) copolymer in patients with acute hemoptysis. Materials and Methods Thirty-four patients (25 male; mean age, 58 y; range, 13–78 y) who underwent BAE with EVOH were retrospectively reviewed. Reasons for acute hemoptysis included lung cancer (44%), pulmonary metastases (12%), bronchiectasis (21%), arteriovenous malformation (5%), tuberculosis (6%), aspergilloma (3%), acute respiratory distress syndrome (3%), anticoagulant overdose (3%), and scar tissue (3%). Technical and clinical success of BAE were retrospectively assessed. Results Embolization was technically successful in 94% of patients. Additional embolization material was needed in 4 patients (12%). The immediate clinical success rate was 94% (32 of 34); in 2 patients (6%), hemoptysis recurred immediately after the intervention or could not be stopped. Periinterventional minor complications included headache (n = 1), fever (n = 1), and acute renal failure (n = 1). During follow-up (mean, 8.8 mo), 5 patients had a recurrence of hemoptysis (15%). Conclusions The use of EVOH copolymer for BAE in patients with acute hemoptysis is technically successful and safe and has a good clinical outcome with a low number of recurrences.

  • transarterial embolization of type ii endoleaks after evar the role of ethylene vinyl alcohol copolymer onyx
    CardioVascular and Interventional Radiology, 2013
    Co-Authors: R Mullerwille, P Heiss, Philipp Wiggermann, O Guntner, Andreas G. Schreyer, Patrick Hoffstetter, Christian Stroszczynski, Walter A. Wohlgemuth, Niels Zorger
    Abstract:

    Purpose To determine the feasibility and efficacy of transarterial endoleak embolization using the Liquid Embolic Agent ethylene vinyl alcohol copolymer (Onyx).

  • Endovascular Treatment of Acute Arterial Hemorrhage in Trauma Patients Using Ethylene Vinyl Alcohol Copolymer (Onyx)
    CardioVascular and Interventional Radiology, 2012
    Co-Authors: René Müller-wille, P Heiss, Patrick Hoffstetter, T. Herold, Ernst Michael Jung, Okka W. Hamer, Janine Rennert, Christian Stroszczynski, A. G. Schreyer, Niels Zorger
    Abstract:

    Purpose This study was designed to determine the feasibility and efficacy of endovascular embolization with Liquid Embolic Agent ethylene vinyl alcohol copolymer (Onyx) in patients with acute traumatic arterial bleeding. Methods This is a retrospective review of 13 patients (9 men and 4 women; mean age 45 years) with severe trauma who underwent embolotherapy using Onyx from November 2003 to February 2009. Bleeding was located in the pelvis (5 patients), kidney (3 patients), mesenteric region (2 patients), retroperitoneal space (2 patients), neck (1 patient), and thigh (1 patient). In three cases (23.1%), Onyx was used in conjunction with coils. We evaluate the technical and clinical success, procedural and embolization time, occurrence of rebleeding, and embolotherapy-related complications, such as necrosis or migration of Onyx into nontarget vessels. Results In all patients, embolotherapy was technically and clinically successful on the first attempt. Control of bleeding could be reached with a mean time of 19 (range, 4–63) min after correct placement of the microcatheter in the feeding artery. No recurrent bleeding was detected. No unintended necrosis or migration of Onyx into a nontarget region was observed. During the follow-up period, three patients (23.1%) died due to severe intracranial hemorrhage, cardiac arrest, and sepsis. Conclusions Transcatheter embolization with new Liquid Embolic Agent Onyx is technically feasible and effective in trauma patients with acute arterial hemorrhage.

  • Endovascular treatment of acute arterial hemorrhage in trauma patients using ethylene vinyl alcohol copolymer (Onyx).
    CardioVascular and Interventional Radiology, 2011
    Co-Authors: René Müller-wille, P Heiss, Andreas G. Schreyer, Patrick Hoffstetter, T. Herold, Ernst Michael Jung, Okka W. Hamer, Janine Rennert, Christian Stroszczynski, Niels Zorger
    Abstract:

    Purpose This study was designed to determine the feasibility and efficacy of endovascular embolization with Liquid Embolic Agent ethylene vinyl alcohol copolymer (Onyx) in patients with acute traumatic arterial bleeding.

Christian Stroszczynski - One of the best experts on this subject based on the ideXlab platform.

  • Treatment of Acute Hemoptysis by Bronchial Artery Embolization with the Liquid Embolic Agent Ethylene Vinyl Alcohol Copolymer
    Journal of vascular and interventional radiology : JVIR, 2017
    Co-Authors: Isabelle Ayx, René Müller-wille, Christian Stroszczynski, Walter A. Wohlgemuth, Michael Pfeifer, Marc Lepiorz, Heinrich Hubauer, Holger Goessmann, Niels Zorger
    Abstract:

    Abstract Purpose To determine the technical and clinical success of bronchial artery embolization (BAE) with the Liquid Embolic Agent ethylene vinyl alcohol (EVOH) copolymer in patients with acute hemoptysis. Materials and Methods Thirty-four patients (25 male; mean age, 58 y; range, 13–78 y) who underwent BAE with EVOH were retrospectively reviewed. Reasons for acute hemoptysis included lung cancer (44%), pulmonary metastases (12%), bronchiectasis (21%), arteriovenous malformation (5%), tuberculosis (6%), aspergilloma (3%), acute respiratory distress syndrome (3%), anticoagulant overdose (3%), and scar tissue (3%). Technical and clinical success of BAE were retrospectively assessed. Results Embolization was technically successful in 94% of patients. Additional embolization material was needed in 4 patients (12%). The immediate clinical success rate was 94% (32 of 34); in 2 patients (6%), hemoptysis recurred immediately after the intervention or could not be stopped. Periinterventional minor complications included headache (n = 1), fever (n = 1), and acute renal failure (n = 1). During follow-up (mean, 8.8 mo), 5 patients had a recurrence of hemoptysis (15%). Conclusions The use of EVOH copolymer for BAE in patients with acute hemoptysis is technically successful and safe and has a good clinical outcome with a low number of recurrences.

  • transarterial embolization of type ii endoleaks after evar the role of ethylene vinyl alcohol copolymer onyx
    CardioVascular and Interventional Radiology, 2013
    Co-Authors: R Mullerwille, P Heiss, Philipp Wiggermann, O Guntner, Andreas G. Schreyer, Patrick Hoffstetter, Christian Stroszczynski, Walter A. Wohlgemuth, Niels Zorger
    Abstract:

    Purpose To determine the feasibility and efficacy of transarterial endoleak embolization using the Liquid Embolic Agent ethylene vinyl alcohol copolymer (Onyx).

  • Endovascular Treatment of Acute Arterial Hemorrhage in Trauma Patients Using Ethylene Vinyl Alcohol Copolymer (Onyx)
    CardioVascular and Interventional Radiology, 2012
    Co-Authors: René Müller-wille, P Heiss, Patrick Hoffstetter, T. Herold, Ernst Michael Jung, Okka W. Hamer, Janine Rennert, Christian Stroszczynski, A. G. Schreyer, Niels Zorger
    Abstract:

    Purpose This study was designed to determine the feasibility and efficacy of endovascular embolization with Liquid Embolic Agent ethylene vinyl alcohol copolymer (Onyx) in patients with acute traumatic arterial bleeding. Methods This is a retrospective review of 13 patients (9 men and 4 women; mean age 45 years) with severe trauma who underwent embolotherapy using Onyx from November 2003 to February 2009. Bleeding was located in the pelvis (5 patients), kidney (3 patients), mesenteric region (2 patients), retroperitoneal space (2 patients), neck (1 patient), and thigh (1 patient). In three cases (23.1%), Onyx was used in conjunction with coils. We evaluate the technical and clinical success, procedural and embolization time, occurrence of rebleeding, and embolotherapy-related complications, such as necrosis or migration of Onyx into nontarget vessels. Results In all patients, embolotherapy was technically and clinically successful on the first attempt. Control of bleeding could be reached with a mean time of 19 (range, 4–63) min after correct placement of the microcatheter in the feeding artery. No recurrent bleeding was detected. No unintended necrosis or migration of Onyx into a nontarget region was observed. During the follow-up period, three patients (23.1%) died due to severe intracranial hemorrhage, cardiac arrest, and sepsis. Conclusions Transcatheter embolization with new Liquid Embolic Agent Onyx is technically feasible and effective in trauma patients with acute arterial hemorrhage.

  • Endovascular treatment of acute arterial hemorrhage in trauma patients using ethylene vinyl alcohol copolymer (Onyx).
    CardioVascular and Interventional Radiology, 2011
    Co-Authors: René Müller-wille, P Heiss, Andreas G. Schreyer, Patrick Hoffstetter, T. Herold, Ernst Michael Jung, Okka W. Hamer, Janine Rennert, Christian Stroszczynski, Niels Zorger
    Abstract:

    Purpose This study was designed to determine the feasibility and efficacy of endovascular embolization with Liquid Embolic Agent ethylene vinyl alcohol copolymer (Onyx) in patients with acute traumatic arterial bleeding.

René Müller-wille - One of the best experts on this subject based on the ideXlab platform.

  • Treatment of Acute Hemoptysis by Bronchial Artery Embolization with the Liquid Embolic Agent Ethylene Vinyl Alcohol Copolymer
    Journal of vascular and interventional radiology : JVIR, 2017
    Co-Authors: Isabelle Ayx, René Müller-wille, Christian Stroszczynski, Walter A. Wohlgemuth, Michael Pfeifer, Marc Lepiorz, Heinrich Hubauer, Holger Goessmann, Niels Zorger
    Abstract:

    Abstract Purpose To determine the technical and clinical success of bronchial artery embolization (BAE) with the Liquid Embolic Agent ethylene vinyl alcohol (EVOH) copolymer in patients with acute hemoptysis. Materials and Methods Thirty-four patients (25 male; mean age, 58 y; range, 13–78 y) who underwent BAE with EVOH were retrospectively reviewed. Reasons for acute hemoptysis included lung cancer (44%), pulmonary metastases (12%), bronchiectasis (21%), arteriovenous malformation (5%), tuberculosis (6%), aspergilloma (3%), acute respiratory distress syndrome (3%), anticoagulant overdose (3%), and scar tissue (3%). Technical and clinical success of BAE were retrospectively assessed. Results Embolization was technically successful in 94% of patients. Additional embolization material was needed in 4 patients (12%). The immediate clinical success rate was 94% (32 of 34); in 2 patients (6%), hemoptysis recurred immediately after the intervention or could not be stopped. Periinterventional minor complications included headache (n = 1), fever (n = 1), and acute renal failure (n = 1). During follow-up (mean, 8.8 mo), 5 patients had a recurrence of hemoptysis (15%). Conclusions The use of EVOH copolymer for BAE in patients with acute hemoptysis is technically successful and safe and has a good clinical outcome with a low number of recurrences.

  • Endovascular Treatment of Acute Arterial Hemorrhage in Trauma Patients Using Ethylene Vinyl Alcohol Copolymer (Onyx)
    CardioVascular and Interventional Radiology, 2012
    Co-Authors: René Müller-wille, P Heiss, Patrick Hoffstetter, T. Herold, Ernst Michael Jung, Okka W. Hamer, Janine Rennert, Christian Stroszczynski, A. G. Schreyer, Niels Zorger
    Abstract:

    Purpose This study was designed to determine the feasibility and efficacy of endovascular embolization with Liquid Embolic Agent ethylene vinyl alcohol copolymer (Onyx) in patients with acute traumatic arterial bleeding. Methods This is a retrospective review of 13 patients (9 men and 4 women; mean age 45 years) with severe trauma who underwent embolotherapy using Onyx from November 2003 to February 2009. Bleeding was located in the pelvis (5 patients), kidney (3 patients), mesenteric region (2 patients), retroperitoneal space (2 patients), neck (1 patient), and thigh (1 patient). In three cases (23.1%), Onyx was used in conjunction with coils. We evaluate the technical and clinical success, procedural and embolization time, occurrence of rebleeding, and embolotherapy-related complications, such as necrosis or migration of Onyx into nontarget vessels. Results In all patients, embolotherapy was technically and clinically successful on the first attempt. Control of bleeding could be reached with a mean time of 19 (range, 4–63) min after correct placement of the microcatheter in the feeding artery. No recurrent bleeding was detected. No unintended necrosis or migration of Onyx into a nontarget region was observed. During the follow-up period, three patients (23.1%) died due to severe intracranial hemorrhage, cardiac arrest, and sepsis. Conclusions Transcatheter embolization with new Liquid Embolic Agent Onyx is technically feasible and effective in trauma patients with acute arterial hemorrhage.

  • Endovascular treatment of acute arterial hemorrhage in trauma patients using ethylene vinyl alcohol copolymer (Onyx).
    CardioVascular and Interventional Radiology, 2011
    Co-Authors: René Müller-wille, P Heiss, Andreas G. Schreyer, Patrick Hoffstetter, T. Herold, Ernst Michael Jung, Okka W. Hamer, Janine Rennert, Christian Stroszczynski, Niels Zorger
    Abstract:

    Purpose This study was designed to determine the feasibility and efficacy of endovascular embolization with Liquid Embolic Agent ethylene vinyl alcohol copolymer (Onyx) in patients with acute traumatic arterial bleeding.

P Heiss - One of the best experts on this subject based on the ideXlab platform.

  • transarterial embolization of type ii endoleaks after evar the role of ethylene vinyl alcohol copolymer onyx
    CardioVascular and Interventional Radiology, 2013
    Co-Authors: R Mullerwille, P Heiss, Philipp Wiggermann, O Guntner, Andreas G. Schreyer, Patrick Hoffstetter, Christian Stroszczynski, Walter A. Wohlgemuth, Niels Zorger
    Abstract:

    Purpose To determine the feasibility and efficacy of transarterial endoleak embolization using the Liquid Embolic Agent ethylene vinyl alcohol copolymer (Onyx).

  • Endovascular Treatment of Acute Arterial Hemorrhage in Trauma Patients Using Ethylene Vinyl Alcohol Copolymer (Onyx)
    CardioVascular and Interventional Radiology, 2012
    Co-Authors: René Müller-wille, P Heiss, Patrick Hoffstetter, T. Herold, Ernst Michael Jung, Okka W. Hamer, Janine Rennert, Christian Stroszczynski, A. G. Schreyer, Niels Zorger
    Abstract:

    Purpose This study was designed to determine the feasibility and efficacy of endovascular embolization with Liquid Embolic Agent ethylene vinyl alcohol copolymer (Onyx) in patients with acute traumatic arterial bleeding. Methods This is a retrospective review of 13 patients (9 men and 4 women; mean age 45 years) with severe trauma who underwent embolotherapy using Onyx from November 2003 to February 2009. Bleeding was located in the pelvis (5 patients), kidney (3 patients), mesenteric region (2 patients), retroperitoneal space (2 patients), neck (1 patient), and thigh (1 patient). In three cases (23.1%), Onyx was used in conjunction with coils. We evaluate the technical and clinical success, procedural and embolization time, occurrence of rebleeding, and embolotherapy-related complications, such as necrosis or migration of Onyx into nontarget vessels. Results In all patients, embolotherapy was technically and clinically successful on the first attempt. Control of bleeding could be reached with a mean time of 19 (range, 4–63) min after correct placement of the microcatheter in the feeding artery. No recurrent bleeding was detected. No unintended necrosis or migration of Onyx into a nontarget region was observed. During the follow-up period, three patients (23.1%) died due to severe intracranial hemorrhage, cardiac arrest, and sepsis. Conclusions Transcatheter embolization with new Liquid Embolic Agent Onyx is technically feasible and effective in trauma patients with acute arterial hemorrhage.

  • Endovascular treatment of acute arterial hemorrhage in trauma patients using ethylene vinyl alcohol copolymer (Onyx).
    CardioVascular and Interventional Radiology, 2011
    Co-Authors: René Müller-wille, P Heiss, Andreas G. Schreyer, Patrick Hoffstetter, T. Herold, Ernst Michael Jung, Okka W. Hamer, Janine Rennert, Christian Stroszczynski, Niels Zorger
    Abstract:

    Purpose This study was designed to determine the feasibility and efficacy of endovascular embolization with Liquid Embolic Agent ethylene vinyl alcohol copolymer (Onyx) in patients with acute traumatic arterial bleeding.

Patrick Hoffstetter - One of the best experts on this subject based on the ideXlab platform.

  • transarterial embolization of type ii endoleaks after evar the role of ethylene vinyl alcohol copolymer onyx
    CardioVascular and Interventional Radiology, 2013
    Co-Authors: R Mullerwille, P Heiss, Philipp Wiggermann, O Guntner, Andreas G. Schreyer, Patrick Hoffstetter, Christian Stroszczynski, Walter A. Wohlgemuth, Niels Zorger
    Abstract:

    Purpose To determine the feasibility and efficacy of transarterial endoleak embolization using the Liquid Embolic Agent ethylene vinyl alcohol copolymer (Onyx).

  • Endovascular Treatment of Acute Arterial Hemorrhage in Trauma Patients Using Ethylene Vinyl Alcohol Copolymer (Onyx)
    CardioVascular and Interventional Radiology, 2012
    Co-Authors: René Müller-wille, P Heiss, Patrick Hoffstetter, T. Herold, Ernst Michael Jung, Okka W. Hamer, Janine Rennert, Christian Stroszczynski, A. G. Schreyer, Niels Zorger
    Abstract:

    Purpose This study was designed to determine the feasibility and efficacy of endovascular embolization with Liquid Embolic Agent ethylene vinyl alcohol copolymer (Onyx) in patients with acute traumatic arterial bleeding. Methods This is a retrospective review of 13 patients (9 men and 4 women; mean age 45 years) with severe trauma who underwent embolotherapy using Onyx from November 2003 to February 2009. Bleeding was located in the pelvis (5 patients), kidney (3 patients), mesenteric region (2 patients), retroperitoneal space (2 patients), neck (1 patient), and thigh (1 patient). In three cases (23.1%), Onyx was used in conjunction with coils. We evaluate the technical and clinical success, procedural and embolization time, occurrence of rebleeding, and embolotherapy-related complications, such as necrosis or migration of Onyx into nontarget vessels. Results In all patients, embolotherapy was technically and clinically successful on the first attempt. Control of bleeding could be reached with a mean time of 19 (range, 4–63) min after correct placement of the microcatheter in the feeding artery. No recurrent bleeding was detected. No unintended necrosis or migration of Onyx into a nontarget region was observed. During the follow-up period, three patients (23.1%) died due to severe intracranial hemorrhage, cardiac arrest, and sepsis. Conclusions Transcatheter embolization with new Liquid Embolic Agent Onyx is technically feasible and effective in trauma patients with acute arterial hemorrhage.

  • Endovascular treatment of acute arterial hemorrhage in trauma patients using ethylene vinyl alcohol copolymer (Onyx).
    CardioVascular and Interventional Radiology, 2011
    Co-Authors: René Müller-wille, P Heiss, Andreas G. Schreyer, Patrick Hoffstetter, T. Herold, Ernst Michael Jung, Okka W. Hamer, Janine Rennert, Christian Stroszczynski, Niels Zorger
    Abstract:

    Purpose This study was designed to determine the feasibility and efficacy of endovascular embolization with Liquid Embolic Agent ethylene vinyl alcohol copolymer (Onyx) in patients with acute traumatic arterial bleeding.